Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma

Ren,Pengfei; Ye,Hua; Dai,Liping; Liu,Mei; Liu,Xinxin; Chai,Yurong; Shao,Qing; Li,Yang; Lei,Ningjing; Peng,Bo; Yao,Wu; Zhang,Jianying

doi:10.3892/or.2013.2714

Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma

Authors:
- Pengfei Ren
- Hua Ye
- Liping Dai
- Mei Liu
- Xinxin Liu
- Yurong Chai
- Qing Shao
- Yang Li
- Ningjing Lei
- Bo Peng
- Wu Yao
- Jianying Zhang
View Affiliations

Affiliations: Henan Key Laboratory of Tumor Epidemiology and College of Public Health, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA
Published online on: September 4, 2013 https://doi.org/10.3892/or.2013.2714
Pages: 2297-2303

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peroxiredoxin 1 (Prdx1) is an antioxidant and plays an important role in H2O2-mediated cell signaling. We previously found that the expression level of Prdx1 was elevated in esophagus squamous cell carcinoma (ESCC) tissue using a proteomics approach. Since overexpressed protein can induce an autoimmune response, to further examine whether serum from ESCC patients exhibits immunoreactivity against Prdx1, autoantibody responses to Prdx1 were evaluated by ELISA, western blotting and indirect immunofluorescence assay in sera from patients with ESCC and normal individuals. Immunohistochemical study with tissue array slides and western blot analysis with cancer cell lines were also performed to analyze the protein expression profiles of Prdx1 in ESCC tissues and cancer cell lines. The results demonstrated that the positive rate of autoantibody against Prdx1 in ESCC sera was 13.2% (9/68), whereas this rate was 0% (0/89) in normal individuals. Data also showed that expression of Prdx1 was significantly increased in ESCC tissues when compared to expression in paired adjacent normal tissues (P<0.05). The data indicate that Prdx1 may contribute to malignant transformation of the esophagus, and may be used as a biomarker in the immunodiagnosis of ESCC.

View Figures

View References

1	Lee SY and Jeoung D: The reverse proteomics for identification of tumor antigens. J Microbiol Biotechnol. 17:879–890. 2007.PubMed/NCBI
2	Fernández Madrid F, Tang N, Alansari H, Karvonen RL and Tomkiel JE: Improved approach to identify cancer-associated autoantigens. Autoimmun Rev. 4:230–235. 2005.
3	Rhee SG: Cell signaling. H₂O₂, a necessary evil for cell signaling. Science. 312:1882–1883. 2006.PubMed/NCBI
4	Rhee SG, Chae HZ and Kim K: Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 38:1543–1552. 2005. View Article : Google Scholar : PubMed/NCBI
5	Neumann CA, Cao J and Manevich Y: Peroxiredoxin 1 and its role in cell signaling. Cell Cycle. 8:4072–4078. 2009. View Article : Google Scholar : PubMed/NCBI
6	Cao J, Schulte J, Knight A, et al: Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. 28:1505–1517. 2009. View Article : Google Scholar : PubMed/NCBI
7	Hoshino I, Matsubara H, Akutsu Y, et al: Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep. 18:867–871. 2007.PubMed/NCBI
8	Zhang J, Wang K, Zhang J, Liu SS, Dai L and Zhang JY: Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res. 10:2863–2872. 2011. View Article : Google Scholar : PubMed/NCBI
9	Kim YJ, Lee WS, Ip C, Chae HZ, Park EM and Park YM: Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res. 66:7136–7142. 2006. View Article : Google Scholar : PubMed/NCBI
10	Kim JH, Bogner PN, Baek SH, et al: Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res. 14:2326–2333. 2008. View Article : Google Scholar : PubMed/NCBI
11	Chang JW, Lee SH, Jeong JY, et al: Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett. 579:2873–2877. 2005. View Article : Google Scholar : PubMed/NCBI
12	Yonglitthipagon P, Pairojkul C, Chamgramol Y, et al: Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma. Hum Pathol. 43:1719–1730. 2012. View Article : Google Scholar : PubMed/NCBI
13	Li J, Yang ZL, Ren X, et al: ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Tumour Biol. 34:359–368. 2013. View Article : Google Scholar : PubMed/NCBI
14	Quan C, Cha EJ, Lee HL, Han KH, Lee KM and Kim WJ: Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol. 175:1512–1516. 2006. View Article : Google Scholar : PubMed/NCBI
15	Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA and Gollnick SO: Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res. 71:1637–1646. 2011. View Article : Google Scholar : PubMed/NCBI
16	Chung KH, Lee DH, Kim Y, et al: Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. J Proteome Res. 9:451–457. 2010. View Article : Google Scholar : PubMed/NCBI
17	Gordis L: Assessing the validity and reliability of diagnostic and screening tests. Epidemiology. 3:71–94. 1996.
18	Das S, Otani H, Maulik N and Das DK: Redox regulation of angiotensin II preconditioning of the myocardium requires MAP kinase signaling. J Mol Cell Cardiol. 41:248–255. 2006. View Article : Google Scholar : PubMed/NCBI
19	Kamata H, Honda S, Maeda S, Chang L, Hirata H and Karin M: Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 120:649–661. 2005.
20	Wen ST and Van Etten RA: The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 11:2456–2467. 1997. View Article : Google Scholar : PubMed/NCBI
21	Neumann CA, Krause DS, Carman CV, et al: Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 424:561–565. 2003. View Article : Google Scholar : PubMed/NCBI
22	Benhar M, Dalyot I, Engelberg D and Levitzki A: Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol. 21:6913–6926. 2001. View Article : Google Scholar
23	Barranco-Medina S, Lázaro JJ and Dietz KJ: The oligomeric conformation of peroxiredoxins links redox state to function. FEBS Lett. 583:1809–1816. 2009. View Article : Google Scholar : PubMed/NCBI
24	Sirvent A, Benistant C and Roche S: Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell. 100:617–631. 2008. View Article : Google Scholar : PubMed/NCBI
25	Mu ZM, Yin XY and Prochownik EV: Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem. 277:43175–43184. 2002. View Article : Google Scholar : PubMed/NCBI
26	Hoskins ER, Hood BL, Sun M, Krivak TC, Edwards RP and Conrads TP: Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation. PLoS One. 6:e250562011. View Article : Google Scholar : PubMed/NCBI
27	Hoshino I, Matsubara H, Hanari N, et al: Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res. 11:7945–7952. 2005. View Article : Google Scholar : PubMed/NCBI
28	Chen MF, Keng PC, Shau H, et al: Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys. 64:581–591. 2006. View Article : Google Scholar : PubMed/NCBI
29	Liu H, Zhang J, Wang S, et al: Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system. Cancer Epidemiol. 36:82–88. 2012. View Article : Google Scholar : PubMed/NCBI
30	Backes C, Ludwig N, Leidinger P, et al: Immunogenicity of autoantigens. BMC Genomics. 12:3402011. View Article : Google Scholar : PubMed/NCBI
31	Tan EM and Zhang J: Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 222:328–340. 2008. View Article : Google Scholar : PubMed/NCBI